{
    "symbol": "CLLS",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-13 11:11:01",
    "content": " Lastly, I'm excited to announce that we anticipate filing an IND this year for UCART20x22, Cellectis first allogeneic dual CAR T-cell product candidate being developed for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. There is a lot of trials ongoing, a lot of different methods that are ongoing using different approaches for lymphodepletion, for CAR expansion, different type of  , etcetera, but we see also that Cellectis has been very interestingly positioned us with our partners, Allogene, Servier, but also Cytovia and Iovance into a fantastic space where we're being leading into this space."
}